HRP20160178T1 - Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze - Google Patents

Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze Download PDF

Info

Publication number
HRP20160178T1
HRP20160178T1 HRP20160178T HRP20160178T HRP20160178T1 HR P20160178 T1 HRP20160178 T1 HR P20160178T1 HR P20160178 T HRP20160178 T HR P20160178T HR P20160178 T HRP20160178 T HR P20160178T HR P20160178 T1 HRP20160178 T1 HR P20160178T1
Authority
HR
Croatia
Prior art keywords
crystalline form
salt
phosphate salt
degrees
benzonitrile
Prior art date
Application number
HRP20160178T
Other languages
English (en)
Croatian (hr)
Inventor
Paul Sutton
Eric Loeser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160178(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20160178T1 publication Critical patent/HRP20160178T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20160178T 2012-01-17 2013-01-15 Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze HRP20160178T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
EP13701194.6A EP2804863B1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (1)

Publication Number Publication Date
HRP20160178T1 true HRP20160178T1 (hr) 2016-03-25

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160178T HRP20160178T1 (hr) 2012-01-17 2013-01-15 Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze

Country Status (40)

Country Link
US (2) US9334276B2 (env)
EP (1) EP2804863B1 (env)
JP (1) JP5749410B2 (env)
KR (2) KR20140093726A (env)
CN (1) CN104039793B (env)
AP (1) AP2014007762A0 (env)
AR (1) AR089728A1 (env)
AU (1) AU2013209952B2 (env)
BR (1) BR112014017260A8 (env)
CA (1) CA2863339C (env)
CL (1) CL2014001863A1 (env)
CO (1) CO7000775A2 (env)
CR (1) CR20140345A (env)
CU (1) CU20140086A7 (env)
CY (1) CY1117914T1 (env)
DK (1) DK2804863T3 (env)
EA (1) EA026232B1 (env)
ES (1) ES2564143T3 (env)
GT (1) GT201400155A (env)
HR (1) HRP20160178T1 (env)
HU (1) HUE026984T2 (env)
IL (1) IL233541B (env)
IN (1) IN2014DN06781A (env)
JO (1) JO3137B1 (env)
MA (1) MA35858B1 (env)
MX (1) MX2014008686A (env)
NZ (1) NZ626277A (env)
PE (1) PE20142358A1 (env)
PH (1) PH12014501638A1 (env)
PL (1) PL2804863T3 (env)
RS (1) RS54589B1 (env)
SG (1) SG11201404061YA (env)
SI (1) SI2804863T1 (env)
SM (1) SMT201600083B (env)
TN (1) TN2014000256A1 (env)
TW (1) TWI609869B (env)
UA (1) UA114803C2 (env)
UY (1) UY34576A (env)
WO (1) WO2013109514A1 (env)
ZA (1) ZA201404314B (env)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
SI3166596T1 (sl) * 2014-07-07 2018-10-30 Novartis Ag Farmacevtske odmerne oblike
HUE054248T2 (hu) 2015-01-29 2021-08-30 Recordati Ag Eljárás kondenzált imidazo-származékok elõállítására
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
EP3532056A1 (en) * 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
CA2127689A1 (en) 1992-01-27 1993-08-05 Marcel A. C. Janssen Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
CA2505752A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent

Also Published As

Publication number Publication date
TN2014000256A1 (en) 2015-09-30
JO3137B1 (ar) 2017-09-20
JP5749410B2 (ja) 2015-07-15
PH12014501638B1 (en) 2014-10-13
NZ626277A (en) 2015-10-30
CO7000775A2 (es) 2014-07-21
CU20140086A7 (es) 2014-12-26
IL233541A0 (en) 2014-08-31
IL233541B (en) 2018-12-31
PL2804863T3 (pl) 2016-06-30
RS54589B1 (sr) 2016-08-31
PE20142358A1 (es) 2015-01-30
BR112014017260A2 (pt) 2017-06-13
MX2014008686A (es) 2014-08-27
CR20140345A (es) 2014-09-09
TWI609869B (zh) 2018-01-01
EP2804863B1 (en) 2015-12-02
ES2564143T8 (es) 2020-11-18
US20140364470A1 (en) 2014-12-11
AU2013209952A1 (en) 2014-07-24
EP2804863A1 (en) 2014-11-26
JP2015503627A (ja) 2015-02-02
UA114803C2 (uk) 2017-08-10
ES2564143T3 (es) 2016-03-18
AU2013209952B2 (en) 2016-09-01
CL2014001863A1 (es) 2014-11-07
UY34576A (es) 2013-09-02
CY1117914T1 (el) 2017-05-17
SG11201404061YA (en) 2014-08-28
EA026232B1 (ru) 2017-03-31
AR089728A1 (es) 2014-09-10
US20160176883A1 (en) 2016-06-23
CA2863339C (en) 2021-03-23
SI2804863T1 (sl) 2016-05-31
GT201400155A (es) 2017-09-28
IN2014DN06781A (env) 2015-05-22
DK2804863T3 (en) 2016-03-07
US9334276B2 (en) 2016-05-10
KR20140093726A (ko) 2014-07-28
EA201491374A1 (ru) 2014-12-30
PH12014501638A1 (en) 2014-10-13
ZA201404314B (en) 2015-08-26
CA2863339A1 (en) 2013-07-25
WO2013109514A1 (en) 2013-07-25
SMT201600083B (it) 2016-04-29
BR112014017260A8 (pt) 2017-07-04
CN104039793B (zh) 2017-05-10
HUE026984T2 (en) 2016-08-29
HK1198536A1 (en) 2015-05-15
AP2014007762A0 (en) 2014-07-31
KR20140141687A (ko) 2014-12-10
CN104039793A (zh) 2014-09-10
MA35858B1 (fr) 2014-12-01
TW201335161A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
PH12014502524B1 (en) Carboxylic acid compounds
GEP201706774B (en) Heterocyclyl compounds
RU2015140619A (ru) Соль производного пиразолохинолина и ее кристалл
FR2988091B1 (fr) Compositions pulverulentes d'un complexe entre un acide et un metal et leur procede de preparation
HRP20160135T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
IL240828A0 (en) Methods for the Production and Synthesis of Conjugated Amino Acid Binding Groups for Compounds Used for Targeted Imaging of Tumors
HRP20170411T1 (hr) Amido spirocilični amidni i sulfonamidni derivati
WO2013004995A8 (en) Pyrimidinone compounds and their use
FR3007582B1 (fr) Procede d'impression ou de depot par atomisation pour la preparation d'une electrode flexible supportee et la fabrication d'une batterie lithium-ion
HRP20210377T1 (hr) Il-2rbeta-selektivni agonisti u kombinaciji s anti-ctla-4 protutijelom ili anti-pd-1 protutijelom
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MD4551B1 (ro) Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
IL233886A (en) Solid anhydrous crystalline form of 6 - (2 - ((4-amino-3- (3-hydroxyphenyl) -1h- pyrazolo [3,4- d] pyrimidine-1-yl) methyl) -3- (2-chlorobenzyl) -4-oxo-3,4 dihydroquinazoline-5-yl) n, n-bis (2-methoxyethyl) hex-5-inamide
UA117122C2 (uk) Хінолонові похідні
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
AR107548A1 (es) Forma cristalina a de agonista de tlr7, su proceso de preparación y uso
MY205261A (en) Stable crystal form of tipiracil hydrochloride and crystallization method for the same
IL235000B (en) Preparations for oral administration and their use for the treatment of motor disorders
SI2796458T1 (en) CRYSTALINIC SODIUM RALTEGRAVIR SOLUTIONS
HK1225712A1 (zh) 作爲溶血磷脂酸受体拮抗剂的酰胺衍生物
RU2014140336A (ru) Иммунологически полезные соли аргинина
MY169064A (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
HK1220444A1 (zh) 拉喹莫德钠晶体和用於制造它们的改进方法
UY37415A (es) Tienouracilos n3-cíclicamente sustituidos y uso de los mismos